A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 in Patients With Chronic Hepatitis B

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Nov 2022 Interim Results assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of APG-1387 in Chinese patients with Chronic Hepatitis B presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
06 Nov 2022 Results published in the Ascentage Pharma Media Release
06 Nov 2022 According to the Ascentage Pharma media release, results from this study presented at the 73rd American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com